Surgical removal of breast tissue, used to treat or prevent breast cancer.
The NHS has approved Enhertu for women with HER2-low metastatic breast cancer in England, following a price deal. The drug can extend median survival and has been available in Scotland since 2023. NICE’s U-turn follows two years of campaigning by charities and clinicians.
CDDFT has disclosed harm to hundreds of patients at its breast unit, with 315 identified as harmed and 77 significantly harmed. The look-back is widening, and a public board meeting will discuss extending the scope. BBC and NHS reporting have spurred new scrutiny and a NCA-police probe is underway.